Free Trial

Oxford Biomedica (OXB) Stock Forecast & Price Target

GBX 344.50
+1.00 (+0.29%)
(As of 07/12/2024 ET)

Oxford Biomedica - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

GBX 410
High ForecastGBX 740
Average ForecastGBX 410
Low ForecastGBX 180
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetGBX 410GBX 431.25GBX 498.75GBX 752.50
Get Oxford Biomedica Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.

OXB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OXB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Oxford Biomedica Stock vs. The Competition

TypeOxford BiomedicaMedical Companies
Consensus Rating Score
2.33
2.71
Consensus RatingHoldModerate Buy
News Sentiment RatingNeutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/21/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperformGBX 740+121.38%
3/20/2024Numis Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHoldGBX 180-3.12%
9/26/2023Liberum Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHoldGBX 350 ➝ GBX 310+6.35%
6/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutralGBX 495+5.68%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:34 PM ET.

OXB Forecast - Frequently Asked Questions

What is Oxford Biomedica's forecast for 2024?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Oxford Biomedica is GBX 410, with a high forecast of GBX 740 and a low forecast of GBX 180.

Should I buy or sell Oxford Biomedica stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares.

Does Oxford Biomedica's stock price have much upside?

According to analysts, Oxford Biomedica's stock has a predicted upside of 51.56% based on their 12-month stock forecasts.

What analysts cover Oxford Biomedica?

Oxford Biomedica has been rated by research analysts at Royal Bank of Canada in the past 90 days.

Do Wall Street analysts like Oxford Biomedica more than its competitors?

Analysts like Oxford Biomedica less than other "medical" companies. The consensus rating for Oxford Biomedica is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how OXB compares to other companies.


This page (LON:OXB) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners